Long-term results of a prospective multicenter phase II study to preserve the larynx function using concomitant boost radiochemotherapy with Carboplatin

Radiotherapy and Oncology

Volumn 89, Issue 1, 2008, Pages 33-37

  Rudat, Volker ^a,f   Eckel, Hans ^b   Volling, Peter ^c   Schröder, Michael ^d   Staar, Susanne ^e   Wallner, Frank ^a   Wannenmacher, Michael ^a   Dietz, Andreas ^f,g  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GENERAL HOSPITAL KLAGENFURT   (Austria)

^c Evangelisches Krankenhaus   (Germany)

^d Staedtisches Krankenhaus Kassel   (Germany)

^e KLINIKUM BREMEN MITTE   (Germany)

^f SAAD SPECIALIST HOSPITAL   (Saudi Arabia)

^g UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Adverse effects; Combined modality therapy; Head and neck cancer; Larynx preservation; Radiotherapy

Indexed keywords

CARBOPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DYSPHAGIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOPHARYNX CANCER; LARYNGECTOMY; LARYNX; LARYNX CANCER; LARYNX EDEMA; LEUKOPENIA; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; TRACHEOTOMY; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 53049093708     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.06.005     Document Type: Article

References (12)

1. Lefebvre J.L., Chevalier D., Luboinski B., Kirkpatrick A., Collette L., and Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88 (1996) 890-899
2. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685-90.
3. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
4. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
5. Rudat V., Dietz A., Nollert J., et al. Acute and late toxicity, tumour control and intrinsic radiosensitivity of primary fibroblasts in vitro of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol 53 (1999) 233-245
6. Rudat V., Dietz A., Schramm O., et al. Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol 53 (1999) 119-125
7. Dietz A., Nollert J., Eckel H., et al. Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study. Hno 50 (2002) 146-154
8. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
9. Forastiere AA, Maor M, Weber RS, et al. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. 2006;24.
10. de la Vega F.A., Garcia R.V., Dominguez D., et al. Hyperfractionated radiotherapy and concomitant cisplatin for locally advanced laryngeal and hypopharyngeal carcinomas: final results of a single institutional program. Am J Clin Oncol 26 (2003) 550-557
11. Hanna E., Alexiou M., Morgan J., et al. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations. Arch Otolaryngol Head Neck Surg 130 (2004) 861-867
12. Mancuso A.A., Mukherji S.K., Schmalfuss I., et al. Preradiotherapy computed tomography as a predictor of local control in supraglottic carcinoma. J Clin Oncol 17 (1999) 631-637